Notably, however, we found that the co-therapy of acyl-GLP-1 (10 nmol kg 1 ) and the acylated GIPR antagonist (1,500 nmol kg 1 ) equally decreased body weight in DIO WT and Per-Gipr KO mice, with superiority of the co-therapy relative to treatment with acyl-GLP-1 alone (Fig
hCiPSC intervention partially restored Bacteroidota abundance
Biomarkers that could identify metabolic disturbances and NAFLD early, as well as supportive therapies, could be beneficial, and to that end I reviewed two current articles: Mardinoglu, M., et
In a country where self medication is normal, a drug this powerful needs a doctor in the conversation, not just a pharmacy counter
On Thursday, ahead of the diabetes conference, Denmark-based biotech firm Zealand Pharma released data that showed a high dose of its experimental weight loss drug petrelintide helped reduce body weight by an average of 8.6% at 16 weeks
This article presents a summary of studies investigating SNAC technology as an absorption enhancer for a number of molecules and, in particular, explores how SNAC, once coformulated with oral semaglutide, facilitates increased absorption and bioavailability
